Company performance
Add to research
Current Price
as of Mar 14, 2025$12.76
P/E Ratio
N/A
Market Cap
$899.09M
- XNCR
Description
Add to research
Xencor, Inc. is a biopharmaceutical company, which engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Monrovia, CA.
Metrics
Add to research
Overview
- HQPasadena, CA
- SectorHealth Technology
- IndustryBiotechnology
- TickerXNCR
- Price$12.76-0.85%
Trading Information
- Market cap$899.09M
- Float93.86%
- Average Daily Volume (1m)614,203
- Average Daily Volume (3m)620,369
- EPS-$3.58
Company
- Revenue$110.49M
- Rev growth (1yr)-36.72%
- Net income-$232.62M
- Gross margin89.04%
- EBITDA margin-150.51%
- EBITDA-$166.30M
- EV$1.23B
- EV/Revenue11.09
- P/EN/A
- P/S7.51
- P/B1.32
- Debt/Equity34.23
Documents
Add to research
SEC Filings
Factset Street Account
Factset